Sandoz invites young entrepreneurs to enter #SandozHACk, a global competition to help solve healthcare access challenges

NovartisSandoz, the Novartis generic and biosimilar pharmaceutical division, announces the launch of Sandoz HACk - Healthcare Access Challenge - a global competition to generate innovative ideas and solutions to help tackle some of the world's most pressing healthcare access problems. The competition is open for entries until November 30, 2016.

"As global healthcare costs continue to rise faster than economic growth, health access will not improve without a major collaborative effort to address the gap, driven by fresh thinking," said Richard Francis, Division Head and CEO of Sandoz. "We believe that the biggest changes often come from amazing, small ideas and with the launch of Sandoz HACk we want to identify, promote and nurture creative ideas from around the world to help reimagine access to healthcare."

Despite the significant advances made in modern medicine, more than two billion people worldwide cannot access the medicines they need and more than 400 million lack access to essential health services.[1] The combined efforts of stakeholders across both public and private sectors, including the pharmaceutical industry, not-for-profit organizations and governments have made significant advances in tackling healthcare access challenges worldwide. But these large scale systemic initiatives need to be supported by community-led change, driven by innovative small scale solutions that can make a big difference. This is why Sandoz is launching Sandoz HACk, inviting people to generate novel solutions to tackle key healthcare access challenges in local communities.

Mobile technology is radically altering how care is delivered and received worldwide and the influence of mobile in healthcare is likely to continue evolving in the future. In its inaugural year, Sandoz HACk encourages today's generation of entrepreneurs and creative thinkers to enter ideas that harness mobile health technologies - M-Health - to help solve relevant local healthcare access challenges.

Sandoz HACk is open for entries from 18-35 year olds around the world. Following a robust judging process, the six finalist entries will be published on OpenIDEO - a global community of leading organizations and individuals working together to design solutions to the world's biggest challenges. Entrants' ideas will be refined and evolved in partnership with this online community before being presented to a panel of judges. Three winners will be chosen and awarded seed funding and mentorship to help bring their ideas to life.

Details of how to enter the competition and the terms and conditions can be found here:
https://www.sandoz.com/making-access-happen

Join the conversation on Twitter and Facebook using #SandozHACk.

About Sandoz
Sandoz is a global leader in generic and biosimilar pharmaceuticals. As a division of the Novartis Group, our purpose is to discover new ways to improve and extend people's lives. We contribute to society's ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. Our portfolio of approximately 1000 molecules, covering all major therapeutic areas, accounted for 2015 sales of USD 10.1 billion. In 2015, our products reached more than 500 million patients and we aspire to reach one billion. Sandoz is headquartered in Holzkirchen, in Germany's Greater Munich area.

About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world.

1. WHO: Health in 2015; Access to Medicine Index 2015

Most Popular Now

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

More stroke patients may receive crucial treatment…

More patients could be eligible for critical treatments to remove or dissolve blood clots that cause strokes, according to a new treatment guideline issued by the America...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Guidelines extended to improve the use of feedback…

Researchers have recommended changes to international guidelines used in the development of clinical trials in an effort to gain information about the impact of the treat...

Cells of 3 advanced cancers die with drug-like com…

Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggres...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]